Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein
نویسندگان
چکیده
منابع مشابه
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
PURPOSE This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T). EXPERIMENTAL DESIGN The strategy used regional administration (i.p.) of a novel targeting molecule composed of four CC49 anti-tumor-associated glycoprotein 72 (TAG-72) single-chain antibodies linked to streptavidin as a fusion protein (CC49 fusion protein); 24 hours later, a synt...
متن کاملProtein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion
J Nucl Med. F. Meredith Sui Shen, Andres Forero, Albert F. LoBuglio, Hazel Breitz, M.B. Khazaeli, Darrell R. Fisher, Wenquan Wang and Ruby Protein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion http://jnm.snmjournals.org/content/46/4/642 This article and updated information are available at: http://jnm.snmjournals.or...
متن کاملIntraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
The application of intraperitoneal (i.p.) radioimmunotherapy to treat i.p. tumor loci has been limited by bone marrow toxicity secondary to circulating radiolabeled antibodies. The generation of novel genetically engineered monoclonal antibodies, which can achieve high tumor uptake and rapid blood clearance, should enhance the therapeutic index of i.p. radioimmunotherapy. In this regard, a nove...
متن کاملCombination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.
Pretarget radioimmunotherapy (RIT) is a multistep strategy for cancer therapy designed to reduce nontarget organ exposure by uncoupling the tumor targeting moiety from the radioactive ligand. Using this approach, we and others have demonstrated objective responses to therapy among patients with non-Hodgkin's lymphoma, with less hematological toxicity than is typically seen at equivalent doses o...
متن کاملIntraperitoneal radioimmunotherapy for ovarian cancer.
Twenty-eight patients with assessable residual ovarian cancer after cytoreductive surgery and chemotherapy received intraperitoneal I-131 labelled monoclonal antibodies. There was no response in eight patients with tumour nodules greater than 2 cm, a partial response in two of the 15 patients with tumour nodules less than 2 cm, and a complete response in three of the other five patients with po...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2005
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-05-0607